Romain Martin - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Romain Martin

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

The Journal of Clinical Investigation|September 11, 2025

Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease modelsEmilie Crouchet, Eugénie Schaeffer, Marine A Oudot, et al.

Egastroenterology|March 24, 2025

Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver diseaseArmando Andres Roca Suarez, Frank Jühling, Julien Moehlin, et al.

Journal of Hepatology|October 29, 2022

Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironmentNatascha Roehlen, Marion Muller, Zeina Nehme, et al.

Pageof 4

Search research articles

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

The Journal of Clinical Investigation|September 11, 2025

Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease modelsEmilie Crouchet, Eugénie Schaeffer, Marine A Oudot, et al.

Egastroenterology|March 24, 2025

Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver diseaseArmando Andres Roca Suarez, Frank Jühling, Julien Moehlin, et al.

Journal of Hepatology|October 29, 2022

Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironmentNatascha Roehlen, Marion Muller, Zeina Nehme, et al.

Pageof 4